Penlac® is Safe and On Target - Penlac® Nail Lacquer
FOR U.S. RESIDENTS ONLY
Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8%: Safe and on target
About Nail Fungus Treatment with Penlac® For People with Diabetes For Healthcare Professionals
Search













Penlac® is Safe and On Target

Penlac® provides targeted efficacy[1]*

  • Rapid mycological cure begins as early as week 12; these results were sustained throughout the entire 48-week study[2]
  • Proven efficacy demonstrated at 48 weeks[1,2]
  • In clinical studies, 12% or fewer patients achieved a clear or almost clear nail at the end of 48 weeks of treatment[1]

Adapted from Penlac® Prescribing Information. Unretouched photographs. Results may vary.

Penlac® is safe and non-systemic[1]

Penlac® safely treats onychomycosis at the site of infection

  • No blood or liver function tests or monitoring are required with Penlac®[1]
  • No liver damage has been reported with Penlac® use[1,3]
  • No drug interactions have been reported with Penlac® use[1,3]
  • No serious treatment-related adverse events occurred with Penlac® during pivotal trials[2]

*In 2 US pivotal trials (48 weeks each); trials were placebo-controlled, double-blind, randomized, and multicenter.[2]
†Clear nail and negative mycology in Pivotal Study 2; in Pivotal Study 1, the complete cure rate was 5.5%.[1]
‡≤10% nail involvement and negative mycology in Pivotal Study 2; in Pivotal Study 1, the almost-clear rate was 6.5%.[1]
§Negative KOH and negative culture in Pivotal Study 2; in Pivotal Study 1, the mycological cure rate was 29%.[1]


Penlac® is indicated in immunocompetent patients with mild to moderate onychomycosis without lunula involvement due to Trichophyton rubrum.
IMPORTANT SAFETY INFORMATION
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).

Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.
For more information, please see Full Prescribing Information for Penlac®

Your privacy
Dermik Laboratories respects your interest in keeping your personal health information private. The information you provide below will be used only for the purpose of sending an email message to the recipient and will not be saved. For more information, see our Privacy Policy.

Your name:

Your email address:

Recipient's email address:






Processing...





Thank you!
Your email has been sent.